top of page
Medvin icon
Medvin Clinical Research

Call Toll Free:
 1 (855) MEDVIN-1

  • Instagram
  • Facebook
  • LinkedIn
Psoriatic Arthritis.png

Psoriatic Arthritis Trial

Multiple studies available for this indication - criteria differs.

An FDA approved medication for Psoriasis is being investigated for the treatment for Psoriatic Arthritis (PsA). One injection every 3 months for 12 months. Psoriatic arthritis is a chronic inflammatory condition that affects the joints, causing pain, swelling, and stiffness. This study aims to evaluate the potential of new therapies in managing PsA symptoms and improving patient outcomes.

Trial Details

participating criteria.png

Participation  Criteria

  • Must have a diagnosis of PsA for at least 6 months.

  • BMI over 27 (Obesity or Overweight)

  • Must have 3 tender, 3 swollen joints

  • Exclusion: Not qualified with a HX of Type 1 or 2 Diabetes

  • Exclusion: Have a prior or planned surgical treatment for obesity

locations.png

Participating Locations

  • Tujunga

  • Menifee

  • Riverside

  • Whittier

  • Apple Valley

  • Covina

compensation.png

  • Earn up to $1,470 (Up to $120-$150 per clinic visit), plus free Dietician Guidance/Consultations throughout the study.

Compensation

medications.png

  • FDA Approved medications: Taltz or Zepbound (weight loss drug). No placebo involved.

Medications

durations.png

  • 1 year study (12 office visits)

Durations

Do you have a diagnosis of Psoriatic Arthritis?
Are you at least 18 years of age?
Do you have a history of malignancy in the past 5 years?
Do you also have Plaque Psoriasis?
Psoriatic Arthritis.png

Psoriatic Arthritis Trial

Multiple studies available for this indication - criteria differs.

​

An FDA approved medication for Psoriasis is being investigated for the treatment for Psoriatic Arthritis (PsA). One injection every 3 months for 12 months. Psoriatic arthritis is a chronic inflammatory condition that affects the joints, causing pain, swelling, and stiffness. This study aims to evaluate the potential of new therapies in managing PsA symptoms and improving patient outcomes.

bottom of page